NOAC: insufficient evidence for left ventricular thrombosis
- EB Virus Could Be Infected by Kiss: A Hidden Threat Linked to Cancer
- The Silent Threat: How Gas Stoves Pollute Our Homes and Impact Health
- Paternal Microbiome Perturbations Impact Offspring Fitness
- New Report Casts Doubt on Maradona’s Cause of Death and Rocks Manslaughter Case
- Chinese academician unable to provide the exact source of liver transplants
- Early Biomarker for Multiple Sclerosis Development Identified Years in Advance
NOAC: insufficient evidence for left ventricular thrombosis
- AstraZeneca Admits for the First Time that its COVID Vaccine Has Blood Clot Side Effects
- Was COVID virus leaked from the Chinese WIV lab?
- HIV Cure Research: New Study Links Viral DNA Levels to Spontaneous Control
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- What is the difference between Atorvastatin and Rosuvastatin?
- How long can the patient live after heart stent surgery?
NOAC: insufficient evidence for left ventricular thrombosis.
New oral anticoagulants (NOAC) are widely used in deep vein thrombosis and pulmonary embolism, but there is still insufficient evidence in left ventricular thrombosis after acute myocardial infarction.
Left ventricular thrombosis is a complication of acute myocardial infarction (AMI) and, if left untreated, is associated with a significant risk of thromboembolism.
The incidence of left ventricular thrombosis in AMI, especially in patients with acute anterior myocardial infarction, can reach 2.7% to 12.3%, and even in patients with acute ST-segment elevation myocardial infarction (STEMI) (11.5% to 43%).
The current guidelines (ESC, ACCF/AHA, ACCP) all recommend the use of vitamin K antagonists (VKA) for anticoagulation therapy for 3 to 6 months.
New oral anticoagulants (NOAC) are widely used in deep vein thrombosis and pulmonary embolism, but there is still insufficient evidence in left ventricular thrombosis after acute myocardial infarction.
Research Introduction
There are currently studies comparing the safety and effectiveness of NOACs and VKA in the treatment of left ventricular thrombosis in patients with AMI.
The study included 2328 consecutive patients who underwent coronary angiography +/- percutaneous coronary intervention (PCI) diagnosed as AMI at the British Heart Center from May 2015 to December 2018. The primary endpoint is the rate of left ventricular thrombolysis; the secondary endpoint is the rate of bleeding.
The results of the study suggested that 101 patients (4.3%) were diagnosed with left ventricular thrombosis. Sixty patients (59.4%) started VKA treatment, and 41 patients (40.6%) received NOAC treatment (including rivaroxaban: 58.5%, apixaban: 36.5%, and idoxaban: 5.0%).
The two groups were matched to baseline, including age, previous history of heart disease (previous myocardial infarction, PCI, coronary artery bypass graft) cardiovascular risk factors (hypertension, diabetes, hypercholesterolemia).
In addition to dual antiplatelet therapy, patients diagnosed with left ventricular thrombosis after AMI are treated with VKA or NOAC on the second to sixth day of hospitalization.
The anticoagulation treatment plan is determined by the attending physician.
The dose of NOAC is used according to the patient’s condition (such as renal function, etc.). Patients taking warfarin keep the international normalized ratio (INR) range at 2.0-3.0.
During the follow-up period (median 2.2 years), the overall rate of left ventricular thrombosis resolution was 86.1%.
At 1 year, the rate of left ventricular thrombolysis in the NOAC group was higher than that in the warfarin group (82% vs 64.4%, P=0.0018, 1 year).
This difference still exists after adjusting the baseline variables after surgery (OR: 1.8, 95%CI: 1.2~2.9). Major bleeding events were significantly lower in the NOAC group than in the VKA group (0% vs 6.7%, P=0.03).
There was no difference in the incidence of systemic thromboembolism between the two groups (5% vs 2.4%, P=0.388).
This study suggests that in the treatment of left ventricular thrombosis after AMI, NOAC patients may have better therapeutic effects and safety than VKA patients.
However, the sample size of this study is still small, and the treatment plan is non-random, so there may still be great confounding factors, and dabigatran treatment is not used in the NOAC plan, so this conclusion may not apply to all NOACs.
NOAC: insufficient evidence for left ventricular thrombosis.
(source:chinanet, reference only)
Disclaimer of medicaltrend.org